In Brief: FDA Antiviral Drugs Advisory Committee
FDA Antiviral Drugs Advisory Committee: Will discuss liposomal antifungal agents during April 3-4 gathering at FDA's Parklawn Building, Conference Rooms D & E. On April 3, open committee discussion is scheduled from 8-11:30 a.m. and 2:30-5:30 p.m. The advisory committee will meet in closed session April 4, according to a March 16 Federal Register notice...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth